Mode
Text Size
Log in / Sign up
N/A N=16 Randomized Double-blind Basic Science

Neural Underpinnings of Turning

Aging

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Duration of Cortical Silent Period (CSP) (ms) — 104.34; 99.71 milliseconds (ms)

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Experimental: Locomotor Learning (Behavioral)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Duration of Cortical Silent Period (CSP) (ms)
104.34; 99.71
PRIMARY
360 Degree Turn Duration From Baseline
0.306; .367
PRIMARY
180 Degree Turn Duration From Baseline
0.11; 0.22
PRIMARY
Resting Motor Threshold (Percent of Machine Output)
56.13; 68.25
SECONDARY
Katz Independence Questionnaire
6; 6

Summary

Older adults and stroke survivors often have difficulty performing complex walking tasks, due in part to changes in the brain. One task often overlooked is turning, which can lead to injury when performed poorly. The investigators will use non-invasive brain stimulation to assess brain activity and relate those observations to turning performance in older adults and stroke survivors.

Eligibility Criteria

Inclusion Criteria

  • age 65 years or older
  • preferred 10m walking speed 35)
  • current cardiovascular, lung or renal disease; diabetes; terminal illness
  • myocardial infarction or major heart surgery in the previous year
  • cancer treatment in the past year, except for nonmelanoma skin cancers and cancers having an excellent prognosis (e.g., early stage breast or prostate cancer)
  • current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder
  • uncontrolled hypertension at rest (systolic > 180 mmHg and/or diastolic > 100 mmHg)
  • bone fracture or joint replacement in the previous six months
  • current participation in physical therapy for lower extremity function or cardiopulmonary rehabilitation
  • current enrollment in any clinical trial
  • difficulty communicating with study personnel, and/or non-English speaking
  • planning to relocate out of the area during the study period
  • clinical judgment of investigative team regarding safety or non-compliance
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05475236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search